HTG Closes Series E Preferred Stock Offering | GenomeWeb

NEW YORK (GenomeWeb News) – RNA-based testing firm HTG Molecular Diagnostics today said it has initially closed its Series E preferred stock offering.

Through a spokesperson, HTG and its investors declined to disclose the amount of the Series E round. Existing investors Novo Ventures, SROne, Merck Capital Ventures, and Fletcher Spaght participated in the round.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.